Vera Therapeutics received FDA accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for progression. The decision is based on a prespecified interim analysis from ORIGIN 3 showing a 46% reduction in proteinuria from baseline and a 42% reduction versus placebo at 36 weeks, alongside a generally tolerable safety profile dominated by infections and local administration reactions. For the IgAN market, the approval marks entry into a dual-pathway approach targeting BAFF and APRIL and sets up competition with upcoming mechanistically similar candidates.